CD274 and neoplasm: The median OS of PE-patients (vs. PA) was 28.6 vs. 21.3 months for CPS ≥ 50 (p = 0.001), 26.6 vs. 19.4 months for CPS ≥ 20 (p = 0.001) and 21.4 vs. 16.8 months for CPS ≥ 1 (p = 0.001): the benefit from PE therapy seemed more evident for higher PD-L1 expression in tumor cells.